Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas (Q54671910)

2 June 2018

title

Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas (English)

1 reference

2 June 2018

1 reference

1 reference

Young Hwa Soung

1

1 reference

2 June 2018

Jong Woo Lee

2

1 reference

2 June 2018

Su Young Kim

3

1 reference

2 June 2018

Si Hyung Seo

4

1 reference

2 June 2018

Won Sang Park

5

1 reference

2 June 2018

Suk Woo Nam

6

1 reference

2 June 2018

Sang Yong Song

7

1 reference

2 June 2018

Joung Ho Han

8

1 reference

2 June 2018

Cheol Keun Park

9

1 reference

2 June 2018

Jung Young Lee

10

1 reference

2 June 2018

Nam Jin Yoo

11

1 reference

2 June 2018

Sug Hyung Lee

12

1 reference

2 June 2018

publication date

7 April 2005

1 reference

2 June 2018

language of work or name

0 references

1 reference

2 June 2018

volume

446

1 reference

2 June 2018

issue

5

1 reference

2 June 2018

page(s)

483-488

1 reference

2 June 2018

A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections

cites work

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

12 December 2020

Cancer statistics, 2004

1 reference

12 December 2020

Epidermal growth factor receptor: mechanisms of activation and signalling.

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Phosphatidylinositol-3-OH kinase as a direct target of Ras

1 reference

12 December 2020

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

12 December 2020

Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung

1 reference

12 December 2020

Blocking oncogenic Ras signaling for cancer therapy

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Targeting RAS signalling pathways in cancer therapy

1 reference

12 December 2020

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

12 December 2020

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

12 December 2020

Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung

1 reference

12 December 2020

Mammalian Ras interacts directly with the serine/threonine kinase Raf

1 reference

12 December 2020

Epidermal growth factor stimulates guanine nucleotide binding activity and phosphorylation of ras oncogene proteins

1 reference

12 December 2020

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

1 reference

12 December 2020

HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer

1 reference

12 December 2020

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

1 reference

12 December 2020

Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer

1 reference

12 December 2020

10.1007/S00428-005-1254-Y

Identifiers

DOI

1 reference

2 June 2018

1 reference

2 June 2018